Navigation Links
Micromet to Present at the RBC Capital Markets Healthcare Conference
Date:12/5/2008

cal trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet is developing blinatumomab in collaboration with MedImmune, a subsidiary of AstraZeneca plc. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT 110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a conventional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet has licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203, which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell- destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. Previous attempts have shown the potential of T cells to treat cancer, but the therapeutic approac
'/>"/>

SOURCE Micromet, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Added to NASDAQ Biotechnology Index
2. Micromet, Inc. Reports Third Quarter 2008 Financial Results
3. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
4. Micromet Closes $40 Million Private Equity Placement
5. Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
6. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
7. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
8. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
9. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
10. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
11. Micromet to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... RESEARCH TRIANGLE PARK, N.C. , July 14, ... company focused on cloud-based drug design and development, ... and development program. The company has been granted ... inhibitors of multiple parasitic targets.  ... at the Argonne Leadership Computing Facility (ALCF), researchers ...
(Date:7/14/2014)... Throughout this past June 100s of ... space, representing 38 countries globally, registered for Xtalks ... Participation in Clinical Trials. Attract. Engage. Retain.” , ... R&D expert, Ken Getz, of Tufts CSDD, who ... through Patient Centricity. , Throughout this complimentary six-part ...
(Date:7/14/2014)... 2014 Minerva Neurosciences (NASDAQ: NERV ... to treat neuropsychiatric diseases and disorders, today announced that ... president of finance and chief accounting officer, effective June ... executive with more than 20 years of experience in ... companies. His background includes the management of compliance and ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 ... registry platform, announced that three PatientCrossroads-based patient ... the Phelan-McDermid Syndrome International Registry; and the ... been awarded contracts by the Patient-Centered Outcomes ... creation of a new health data network ...
Breaking Biology Technology:Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3
... Suzanne DeCann visits the University of Wisconsin-Eau Claire ... to pick up her newly earned Master of Business Administration ... the first 11 UW-Eau Claire students to earn their MBAs ... shell get her first real look at the campus and ...
... South Carolina , a health insurance provider that ... its evolving document communication needs by designating two ... Esker DeliveryWare Platform and Esker Fax respectively provide ... fax. , ,BlueCross BlueShield has enlisted Esker software ...
... Middleton-based provider of testing instruments used in support of ... announced the purchase of Masthead Imagings assets. ... are the PIPSpro software package and QC-3 phantom, for ... PIPSpro software displays, enhances and analyzes portal images and ...
Cached Biology Technology:UW-Eau Claire graduates first online MBAs 2UW-Eau Claire graduates first online MBAs 3Blue Cross BlueShield of South Carolina implements Esker solutions 2Standard Imaging acquires Canadian PIPSpro radiation treatment technologies 2
(Date:7/14/2014)... How does oxygen control insect body size? What influence does ... first issue of Current Opinion in Insect Science ... questions. , Current Opinion in Insect Science is ... is a review journal that aims to provide specialists with ... of information published in the field of insect science. First ...
(Date:7/14/2014)... Biogerontology Research Foundation (BGRF), a UK-based charity founded ... of a rapidly ageing population, hosted the inaugural ... with Aging Analytics, a company supporting financial decision-making ... The speakers at the forum included: , Dmitry ... on ,Impact Investment to Advance Longevity Research, , ...
(Date:7/14/2014)... Kansas scientists to the discovery and description of Rhipidocyrtus ... specimen, which turned out to represent a new genus and ... wedge beetle from Borneo is discussed in a recent paper ... . , The holotype male, and only known specimen of ... Borneo but subsequent to this it was transferred among several ...
Breaking Biology News(10 mins):BGRF hosts inaugural 21st Century Medicine Forum 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 3
... N.C. Feb. 28, 2013 Researchers at Wake ... special population of adult stem cells in bone marrow ... intestine and produce intestinal cells, suggesting their potential to ... (IBD). Up to 1 million Americans have IBD, ...
... -- In a new study, biologists will investigate the ... has killed a record number of frogs, toads and ... received a $595,000 grant from the National Science Foundation ... and a fungus called Batrachochytrium dendrobatidis (Bd). ...
... decimate the normal intestinal microbiota, which may never ... the GI tract vulnerable to being colonized by ... New York, NY, and Centro Superior de Investigacin ... normal microbial diversity largely eliminated vancomycin-resistant enterococci (VRE) ...
Cached Biology News:Research supports promise of cell therapy for bowel disease 2Biologists explore link between amphibian behavior and deadly disease 2Biologists explore link between amphibian behavior and deadly disease 3Good bacteria may expunge vancomycin-resistant bacteria from your gut 2
... of Taq DNA polymerase. It is a ... Expressed from a gene construct in E. ... 5'-3' exonuclease domain of the DNA polymerase-encoding ... and even more heat-stable DNA polymerase activity ...
... (ELISA) test kits are qualitative one-step kits ... of drugs and/or their metabolites in forensic ... use only. It is recommended that all ... method such as GC/MS. The simple ...
... inhibitor that noncovalently binds and inactivates neutral pancreatic ... RNase 1, T1, T2, H, U1, U2 or ... inhibitor in that it has a more robust ... RNase in the absence of DTT or other ...
...
Biology Products: